Seems like this is the time to look back upon your year. Here’s a thread on my tweets from 2019 that I’d like to share again with the new followers. No particular order. Here’s the first one: medscape.com/viewarticle/91… I learned a lot by reading all the comments to this piece.
The next tweet is a little sad because it’s true:
I hope every December continues to bring good news such as these:
I find this study very important because the regulators continue to applaud themselves for approving more drugs. That’s not and should not be considered a measure of success.
If you lower the bar, increased number of drug approvals is simply a consequence. sciencedirect.com/science/articl…
I have a dream.
A little uneasy moment of 2019.
Let’s change the phrase “significantly better” to “statistically better”.
And while we are at it, let’s also replace PFS with PFD.
And here’s a YouTube video of one of my most popular lectures from 2019.
And my first interview to a Canadian media:
On non-inferiority trials in oncology.
And on cost-effectiveness of cancer drugs.
Tragicomedy
From my #asco19 talk.
Highlights of ASCO meeting.
Our JAMA IM study on Accelerated approval of cancer drugs. Even made it to CNN: cnn.com/2019/05/28/hea…
Failed P3 RCTs of cancer drugs.
Non inferiority trials again.
